Funding Announcement
KymaThera Raises $80M to Advance K-1728 Into the Clinic
KymaThera raised an $80M Series B to move K-1728 into Phase 1, targeting PI3Kα-mutant breast cancer and vascular malformations.
Jesse Landry
Browse all DevCuration articles — funding news, startup spotlights, AI coverage, developer tools, and expert analysis of the tech ecosystem.